NasdaqGS:CGONBiotechs
CG Oncology Leadership Shift Puts Focus On Valuation Gap And Execution
CG Oncology (NasdaqGS:CGON) announced that President & Chief Operating Officer Ambaw Bellete will separate from the company.
CEO Arthur Kuan will take on the additional role of President, consolidating top leadership responsibilities.
The company has begun a search for a Chief Commercial Officer, signaling changes to its commercial leadership structure.
For investors tracking CG Oncology, the leadership update comes with the stock trading at $62.29 and a year-to-date return of 49.1%. Over...